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Phase II Study of Cediranib in Patients with Malignant
Pleural Mesothelioma
SWOG S0509
Linda L. Garland, MD,* Kari Chansky, MS,† Antoinette J. Wozniak, MD,‡ Anne S. Tsao, MD,§
Shirish M. Gadgeel, MD,‡ Claire F. Verschraegen, MD, Marco A. DaSilva, MD,¶
Mary Redman, PhD,† and David R. Gandara, MD#
Introduction: Malignant pleural mesothelioma (MPM) tumors ex-
press vascular epithelial growth factor (VEGF) and VEGF receptors.
We conducted a phase II study of the oral pan-VEGF receptor
tyrosine kinase inhibitor, cediranib, in patients with MPM after
platinum-based systemic chemotherapy.
Methods: Patients with MPM previously treated with a platinum-
containing chemotherapy regimen and a performance status 0 to 2
were eligible for enrollment. Cediranib 45 mg/d was administered
until progression or unacceptable toxicity. The primary end point
was response rate. Tumor measurements were made by RECIST
criteria, with a subset analysis conducted using modified RECIST. A
two-stage design with an early stopping rule based on response rate
was used.
Results: Fifty-four patients were enrolled. Of 47 evaluable patients,
4 patients (9%) had objective responses, 16 patients (34%) had
stable disease, 20 patients (43%) had disease progression, 2 patients
(4%) had symptomatic deterioration, and 1 patient (2%) had early
death. The most common toxicities were fatigue (64%), diarrhea
(64%), and hypertension (70%); 91% of patients required a dose
reduction. Median overall survival was 9.5 months, 1-year survival
was 36%, and median progression-free survival was 2.6 months.
Conclusion: Cediranib monotherapy has modest single-agent activ-
ity in MPM after platinum-based therapy. However, some patient
tumors were highly sensitive to cediranib. This study provides a
rationale for further testing of cediranib plus chemotherapy in MPM
and highlights the need to identify a predictive biomarker for
cediranib.
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Malignant pleural mesothelioma (MPM) is a neoplasmthat originates in the parietal pleura and is strongly
associated with asbestos exposure through chronic environ-
mental or occupational exposure. The lag time between
exposure and presentation of the disease ranges between 5
and 20 years, although cases have been diagnosed more than
40 years after exposure.1 MPM is a rare cancer with 2000 to
3000 new cases diagnosed in the United States per year; it is
estimated that the incidence of MPM in the United States is
currently peaking.2 Worldwide, however, less stringent reg-
ulation of occupational asbestos has resulted in the continued
exposure of large populations to asbestos and has, therefore,
fostered continued increases in new cases of MPM in Aus-
tralia, Europe, and Asia.3–5
MPM is a relatively chemotherapy- and radiation-re-
sistant tumor. The median survival for untreated patients is in
the range of 4 to 12 months.6 Currently, platinum-based
therapy in combination with newer generation antifolate
drugs such as raltitrexed and pemetrexed remains a bench-
mark for standard front-line therapy for MPM, with median
survival times of 11.4 and 12.1 months, respectively, reported
in phase III trials in combination with cisplatin.7,8 At this
time, there are no well-accepted standard therapies in the
setting of second-line MPM, and no targeted therapies have
been approved for clinical application in MPM.
In preclinical models with MPM cell lines, vascular
epithelial growth factor (VEGF) and its cognate receptors,
VEGF receptor (VEGFR)1 (flt) and VEGFR2 (KDR), are
highly expressed on tumor cells, and a proposed autocrine
growth loop involving VEGF and its cognate receptors has
been identified.9 Recombinant human VEGF added to MPM
cell line cultures stimulates cell proliferation in a dose-
dependent manner, whereas inhibitors of VEGF and VEGF-C
inhibit mesothelioma cell growth.10,11 In support of this
autocrine growth loop, human MPM tumors express the
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angiogenic cytokines VEGF, fibroblast growth factor-1, fi-
broblast growth factor-2, and transforming growth factor-
,12,13 and the coexpression of VEGF and VEGFR1 in human
MPM has been reported.14 In clinical studies, patients with
MPM have high circulating levels of VEGF.15 Some studies
have reported tumor VEGF expression and tumor microves-
sel density to be independent prognostic markers.13,15 These
data support the targeting of tumor angiogenesis as a thera-
peutic strategy in MPM.
Cediranib (Recentin, AZD2171; AstraZeneca Pharma-
ceuticals, Cheshire, United Kingdom) is an orally active,
potent, tyrosine kinase inhibitor (TKI) of VEGFR1 to 3 at
nanomolar concentrations, as well as c-Kit and platelet-
derived growth factor receptor-.16,17 In phase I studies, the
maximum tolerated dose was defined as 20 to 45 mg daily,
with reported dose-limiting toxicities of proteinuria, diarrhea,
thrombocytopenia, hypertension, and hypertensive crisis.18–20
Partial tumor responses and disease stabilization have been
observed in a number of solid tumors.18–21
Given that tumor angiogenesis is a potential therapeutic
target in MPM and that cediranib has shown tolerability and
antitumor efficacy in a number of solid tumors, we performed
a phase II trial of cediranib in patients with advanced or
recurrent MPM after platinum-based chemotherapy. The pri-
mary objective of the trial was to assess the objective re-
sponse rate of cediranib in second-line MPM. Secondary
objectives were to measure survival outcomes and to define
the toxicity profile of cediranib in this setting. A protocol
amendment was made to also capture tumor response by
modified RECIST for pleural tumors.22
PATIENTS AND METHODS
Inclusion Criteria
Patients who were at least 18 years of age with histo-
logically proven epithelioid, sarcomatoid, or biphasic meso-
thelioma of the pleura (by pathology evaluation at local
institutions) whose disease was not resectable were eligible
for enrollment. Patients were required to have had prior
platinum-based chemotherapy, and only one prior chemother-
apy regimen was allowed. Only patients with measurable
disease by RECIST criteria23 were eligible. Prior radiation or
surgical procedures for MPM for diagnostic or therapeutic
purposes were allowed. A Zubrod performance status of 0 to
2 and adequate hematologic function (absolute neutrophil
count 1500/ml and platelets 100,000/ml), hepatic func-
tion (serum bilirubin  upper limit of normal and transami-
nases 1.5 times upper limit of normal), and renal function
(serum creatinine 1.5 times upper limit of normal or a
measured creatinine clearance 50 ml/min) were required.
Patients were not eligible if they had severe systemic
comorbid disease or a significant cardiac history, uncon-
trolled hypertension, significant proteinuria, a prolonged QTc
interval, were either pregnant or breast-feeding, or had gas-
trointestinal tract disease resulting in inability to take oral
medication or altered gastrointestinal absorption.
The protocol and informed consent document were
approved by the Cancer Therapy Evaluation Program of the
National Cancer Institute and the institutional review boards
of participating SWOG member sites. Written informed con-
sent was obtained from all patients before enrollment. This
study was monitored by the Data and Safety Monitoring
Committee of the Southwest Oncology Group.
Study Design and Protocol Treatment
The S0509 treatment protocol (ClinicalTrials.gov_
Identifier: NCT00243074) consisted of single-agent cediranib
administered orally at 45 mg/d every day and were treated
until progression or unacceptable toxicity. Adverse events
were graded according to the NCI CTC Version 3.0. Sequen-
tial dose modifications to 30 mg (dose level 1) and 20 mg
daily (dose level 2) were allowed, although a further dose
reduction to 10 mg daily was allowed for patients on study
3 months who were benefiting from treatment. A treatment
delay until toxicity resolved to  grade 1, and dose modifi-
cations were made for patients with  grade 3 nonhemato-
logic and/or grade 4 hematologic toxicities, and moderate
hypertension and proteinuria.
Patient history, physical examination, hematologic, and
chemical laboratory analyses were performed before cycle 1
of therapy and each subsequent treatment cycle. Radio-
graphic tumor measurements were performed after every two
treatment cycles. Tumor responses were judged by RECIST.
A protocol amendment was made to capture tumor measure-
ments using the modified RECIST measurement system.
Patients were withdrawn from the study due to disease
progression or symptomatic deterioration, unacceptable tox-
icity as assessed by the study physician, treatment delay of
greater than 3 weeks, or if more than the prescribed dose
modifications were required.
Statistical Considerations and Statistical
Analysis
A two-stage design was used such that 20 patients
would be enrolled in the first stage, with an evaluation of
response rate and safety performed. If at least one confirmed
partial response (PR) was noted, the study would continue
accrual to a total of 40 patients. A response rate of 20% or
higher would be sufficient to declare this regimen worthy of
further study, whereas a response rate of 5% or lower would
indicate no further interest in this setting. This design has
a significance level (probability of false declaring an agent
with a true 5% response probability to warrant further
study) of 5% and a power (probability of correctly declar-
ing an agent with a 20% response probability to warrant
further study) of 92%.
Progression-free survival (PFS) was calculated as the
time elapsed between study enrollment and first documented
tumor progression, death, or last contact. Overall survival
(OS) was defined as the time elapsed between study enroll-
ment and death from any cause or last contact. Patients alive
or progression free at last contact were censored for the
respective outcomes. Median PFS and OS, 95% confidence
intervals (CIs), and associated survival curves were estimated
by Kaplan-Meier methods.
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RESULTS
Patients
Patient recruitment was undertaken from November
2005 through April 2008, with a 3-month temporary closure
for the first-stage evaluation. A total of 54 patients were
registered, with 48 patients eligible for enrollment. One
patient was not assessable because of refusal of treatment.
Patient characteristics for the 47 patients are presented in
Table 1. The median age was 66.8 years (range 43–84 years);
the majority of patients were men. Racial composition was
predominantly white (94%) with 6% race not available.
Ethnic composition was Hispanic 4%, non-Hispanic 87%,
and unknown 9%. Patient performance status was 0 in 34%,
1 in 53%, and 2 in 13% of patients. The majority of patients
had less than 5% loss of body weight within the 6 months
before enrollment.
Tumor histologic subtype was classified as epithelioid
(60%), biphasic (6%), and mesothelioma, not otherwise spec-
ified (23%) by local institution pathology review. No patients
with sarcomatoid subtype were enrolled. Histologic subtype
was not reported for 11%. A formal central pathology review
was not performed. All patients had multiagent first-line
chemotherapy.
Response and Survival
There was one patient with an objective response in the
first 20 accrued to the first stage of the trial. The second stage
of the study was then opened for accrual as per the study
design mentioned earlier in the text. For the entire study
cohort (first and second stages combined), response was not
able to be determined because of inadequate assessment for
four patients (8%). These four patients are assumed to be
nonresponders and are included in calculations of response
rate. For the 43 evaluable patients, response data are summa-
rized in Table 2. There were no complete responses. Four
patients (9%) had PRs, including two patients with bulky
disease who had 91% (see Figures 1A, B) and 56% tumor
shrinkage. Sixteen patients (34%) had stable disease (SD),
FIGURE 1. A and B, Computed tomography scans of the
thorax over the course of cediranib therapy.
TABLE 1. Patient Characteristics
N  47 n (%)
Median age (yr) 66.8 (range 43–84)
Men:women (%) 38:9 (81:19)
Zubrod performance status
0 16 (34)
1 25 (53)
2 6 (13)
Six-month before weight loss
5% 33 (70)
5 to 20% 8 (17)
20% 2 (4)
Not reported 4 (9)
Histologic subtype
Epitheliod 28 (60)
Sarcomatoid 0
Biphasic 3 (6)
Not otherwise specified 11 (23)
Not reported 5 (11)
TABLE 2. Antitumor Activity—Best Overall Response
N  43 n (%)
CR 0
PR 4 (9)
SD 16 (34)
PD 20 (43)
Symptomatic deterioration 2 (4)
Early death 1 (2)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
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documented at least 6 weeks after registration and before
progression or symptomatic deterioration (range 2.4–13.7
months). Twenty patients (43%) had progressive disease, two
patients (4%) had symptomatic deterioration, and one patient
(2%) had early death. A waterfall plot of best response is
shown in Figure 2.
OS for 47 patients is shown in Figure 3. Forty-three
patients had died at the time of analysis; the median OS was
9.5 months (95% CI: 5.6–10.7 months) and 1-year survival
was 36% (95% CI: 23–50%). PFS is shown in Figure 4.
Forty-seven patients have progressed or died. Median PFS
was 2.56 months (95% CI: 1.74–3.68 months) and 1-year
PFS was 4% (95% CI: 1–13%). For 16 patients with SD,
median time to progression was 4.9 months (95% CI: 3.6–5.4
months).
For 11 patients, modified RECIST data were reported.
There was 100% correlation in response assessment for
modified RECIST with RECIST measurements.
Adverse Events
Forty-seven patients were evaluable for adverse events.
Hematological adverse events attributed to cediranib were
infrequent and of grades 1 and 2 only (Table 3).
Grades 1 to 4 nonhematological adverse events that
occurred in 9% of patients attributable to study treatment
are listed in Table 4; the most common nonhematologic
adverse events were fatigue, hypertension, and diarrhea.
Grade 3 and 4 events of frequency less than 9% included
apnea, ataxia, cognitive disturbance, intestinal pain, colitis,
dizziness, encephalopathy, esophageal necrosis, ileal perfo-
FIGURE 2. Waterfall plot of best
response.
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FIGURE 3. Progression-free survival.
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ration, hand-foot syndrome, hypokalemia, hyponatremia, hy-
potension, chest wall pain, memory impairment, elevated
serum ammonia, generalized muscle weakness, pain not oth-
erwise specified, tumor pain, renal failure, speech impair-
ment, and thrombosis/embolism. Biochemical abnormalities
were infrequent and of grades 1 and 2 only (Table 5). There
were no treatment-related deaths.
A dose deescalation was made in 43 of 47 patients. Six
patients were removed from the study due to adverse events
attributed to treatment with cediranib. Two patients withdrew
from the study for reasons not related to adverse events.
Thirty-six patients were withdrawn for disease progression,
two patients died early, and one patient was withdrawn for
unspecified reasons.
DISCUSSION
Interest in studying the antiangiogenic agent, cediranib,
in MPM was based on a significant body of evidence sup-
porting the role of angiogenesis as an important growth
signaling pathway for MPM. In the second-line setting, the
objective response rate for single-agent cediranib was 9%,
which did not meet the prespecified 20% response rate of
interest. Notably, however, there was marked shrinkage of
bulky tumors in two of the four patient responders. In this
uncontrolled trial, 34% of patients had SD, yielding a clinical
benefit rate (complete response, PR, and SD) of 43%, which
compares favorably to the clinical benefit rate of 46.6% for
second-line pemetrexed in patients enrolled in an expanded
access program, but less favorably to that reported for sec-
ond-line pemetrexed (clinical benefit rate of 59.3%) in a
0%
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FIGURE 4. Overall survival.
TABLE 3. Hematological Toxicity
N  47
Grades
Percentage
of Patients1 2
Anemia 5 1 13
Leukopenia 1 0 2
Neutropenia 1 0 2
Thrombocytopenia 7 0 15
TABLE 4. Grade 1 to 4 Nonhematological Toxicity (9%
Frequency)
N  47
Grades
Percentage
of Patients1 2 3 4
Constitutional
Anorexia 7 5 3 0 32
Weight loss 7 5 2 0 30
Fatigue 13 10 7 0 64
Dehydration 0 3 3 0 13
Gastrointestinal
Nausea 10 4 2 0 34
Vomiting 5 3 1 0 19
Diarrhea 14 12 4 0 64
Constipation 4 1 1 0 13
Heartburn 3 2 0 0 11
ENT
Dry mouth 4 1 0 0 11
Voice changes 14 3 0 0 36
Cardiac
Hypertension 5 14 14 1 70
Respiratory
Cough 5 1 0 0 13
Renal
Proteinuria 8 4 2 0 30
Musculoskeletal
Muscle pain 3 1 0 0 9
Neurologic
Headache 4 1 1 0 13
Sensory neuropathy 3 0 1 0 9
Endocrine
Hypothyroidism 2 4 0 0 13
ENT, ear, nose, and throat.
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phase III study of second-line pemetrexed versus best sup-
portive care in MPM.24,25 The utility of the clinical benefit
rate derived from single arm phase 2 studies is limited by the
variable natural history of untreated MPM. Thus, there is
great interest in the development and validation of functional
imaging studies and surrogate biomarkers of antitumor activ-
ity to augment the assessment of antiangiogenics and other
classes of agents that might be cytostatic for cohorts of
patients with MPM.
For the entire study population, the median PFS was
short (2.56 months) but similar to reported time to progres-
sion for other targeted agents in MPM.26–28 Specifically, the
clinical efficacy reported in this study for cediranib is in line
with other multitargeted VEGFR receptor TKI agents. In
single-agent studies, front-line vatalanib for pleural and peri-
toneal mesothelioma yielded a response rate of 11% and a
3-month PFS of 55%; front-line/s-line sorafanib therapy for
pleural and peritoneal mesothelioma yielded a response rate
of 4% and a median failure-free survival of 3.7 months; and
second-line sunitinib in MPM yielded a response rate of 23%
with a median time to progression of 3.5 months.29–31 In
contrast, bevacizumab, a monoclonal antibody that blocks
VEGF ligand binding to the VEGFRs, did not have meaningful
clinical activity when combined with the EGFR inhibitor erlo-
tinib in previously treated MPM, nor did bevacizumab enhance
the activity of gemcitabine/cisplatin chemotherapy for front-line
treatment of pleural/peritoneal mesothelioma in the intent to
treat population.32,33 However, in subgroup analysis, patients
on the bevacizumab/gemcitabine/cisplatin arm who had low
circulating levels of VEGF had longer PFS and OS.
In this study of patients with a good performance status
after one platinum-based prior systemic therapy, cediranib
was not well tolerated at the starting dose of 45 mg daily, and
the majority of patients required a dose reduction. In fact,
in several phase I studies of cediranib in solid tumor
patients, the maximum tolerated dose was reported to be
lower than 45 mg.19,20 The safety profile of cediranib as a
second-line agent in MPM was similar to that already
reported for this and other VEGFR TKIs.
MPM is a difficult tumor to measure accurately, as are
other pleural-based tumor types, given the nonspherical pat-
tern of growth. The limitations of RECIST in assessing
response and outcome measures such as PFS have been
documented for MPM.34 Other measurement systems pro-
posed for pleural tumors include modified RECIST, in which
pleural thickness is measured perpendicular to the chest wall
and mediastinum.22 We captured modified RECIST measure-
ments for a small subset of patients and found that tumor
response measured by modified RECIST correlated well with
that measured by RECIST. For this subset, assessment of the
activity of single-agent cediranib was not influenced by
measurement system.
Because MPM is relatively resistant to standard cyto-
toxic chemotherapy, there is great interest in pursuing strat-
egies that would improve the chemosensitivity of MPM.
Antiangiogenic agents can augment the activity of cytotoxic
chemotherapy; one proposed mechanism is through the mod-
ulation of tumor interstitial fluid pressure (TIFP) as in vivo,
elevated TIFP is a barrier to drug delivery to the tumor.35
Both VEGF and platelet-derived growth factor contribute to
increased TIFP, whereas inhibitors of VEGF and/or platelet-
derived growth factor signaling can reduce TIFP and augment
chemotherapy effects in vivo.36–41 The addition of cediranib
to cytotoxic chemotherapy in solid tumors is feasible as
shown in a number of phase I studies,42,43 and an augmenta-
tion of the effect of chemotherapy by cediranib was reported
in a randomized phase II study in non-small cell lung cancer,
whereas the addition of cediranib to paclitaxel plus carbopla-
tin resulted in improved tumor responses and PFS for cedi-
ranib compared with placebo and chemotherapy. Toxicities in
the experimental arm led to a significant number of dose
reductions, thus highlighting the challenges of adding tar-
geted antiangiogenics to standard chemotherapy.44
In summary, the activity of cediranib monotherapy in
MPM after platinum-based therapy was modest, although we
identified a small subset of patients with MPM whose tumors
seem to be highly driven by angiogenic signaling, thus
conferring high sensitivity to this agent. The challenge re-
mains to develop strategies that would enable the selection of
patients with MPM for treatment with targeted antiangiogenic
therapies. Although a large number of potentially predictive
biomarkers for response to antiangiogenic therapy have been
studied, none have been validated for routine clinical use.
Given the signal of activity of single-agent cediranib reported
in this study, and the potential of antiangiogenics to augment
the activity of cytotoxic chemotherapy, the Southwest Oncol-
ogy Group has initiated a phase I/randomized phase II clinical
trial of cediranib versus placebo in combination with pem-
etrexed/cisplatin for first-line treatment of MPM. Both tumor-
based and surrogate biomarkers of angiogenesis will be
collected in the context of this study, to elucidate biomarkers
that may allow for the personalization of antiangiogenic
therapy in MPM.
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TABLE 5. Biochemical Toxicity
N  47
Grades
Percentage
of Patients1 2
Creatinine 3 2 11
Alkaline phosphatase 4 1 11
Alanine aminotransferase 7 1 17
Aspartate aminotransferase 6 2 17
Hyperglycemia 5 1 13
Hypoalbuminemia 4 1 11
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